Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK2 | O95069 | 2/20 | 0.64 |
| ▸ | KCNK10 | P57789 | 2/20 | 0.64 |
| ▸ | SERPINE1 | P05121 | 7/20 | 0.64 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.64 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.64 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.64 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.64 |
| ▸ | ACLY | P53396 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | METAP2 | P50579 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17166275 | 0.92 | AKR1C2 (0.73) | KCNK2KCNK10SERPINE1AKR1C2AKR1C1 | |
| SCHEMBL6350175 | 0.88 | ACLY (0.79) | KCNK2KCNK10SERPINE1AKR1C2AKR1C1 | |
| SCHEMBL6348852 | 0.88 | AKR1C2 (0.72) | KCNK2KCNK10SERPINE1AKR1C2AKR1C1 | |
| SCHEMBL9513479 | 0.86 | MAPT (0.80) | KCNK2KCNK10SERPINE1AKR1C2AKR1C1 | |
| SCHEMBL6352359 | 0.86 | METAP2 (0.71) | KCNK2KCNK10SERPINE1AKR1C2AKR1C1 | |
| SCHEMBL1308635 | 0.86 | AKR1C2 (0.65) | KCNK2KCNK10AKR1C2AKR1C1AKR1C4 | |
| SCHEMBL6360570 | 0.85 | KCNK2 (0.68) | KCNK2KCNK10AKR1C2AKR1C1AKR1C4 | |
| SCHEMBL6350407 | 0.85 | KCNK2 (0.64) | KCNK2KCNK10SERPINE1AKR1C2AKR1C1 | |
| SCHEMBL19554148 | 0.85 | DHODH (0.70) | KCNK2KCNK10SERPINE1AKR1C2AKR1C1 | |
| SCHEMBL6349749 | 0.85 | ACLY (0.58) | KCNK2KCNK10SERPINE1AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | claimed |
| US-8053454-B2 | Pyridopyrimidinone inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | EXELIXIS, INC. (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2004022525-A1 | AMIDE DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042918-A1 | Pyridopyrimidinone Inhibitors of PIM-1 and/or PIM-3 | PIM1, PIM3, PIM2 | KCNK2 952/4885KCNK10 1098/4885SERPINE1 2130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.